Evidence reviews – February 2023
The following documents contain the evidence that was used to develop the 2023 recommendations:
- Patient information and support
- Pharmacological interventions to reduce progression to dysplasia or cancer
- Endoscopic surveillance using white light endoscopy
- Diagnostic accuracy of endoscopic surveillance techniques
- Non-endoscopic surveillance techniques
- Frequency and duration of endoscopic surveillance
- Endoscopic and radiological staging techniques
- Endoscopic treatment (high-grade dysplasia and stage 1 adenocarcinoma)
- Endoscopic treatment (low-grade dysplasia and indefinite dysplasia)
- Endoscopic and radiological follow-up after treatment
- Oesophagectomy versus endoscopic treatment
- Non-surgical treatment for T1b oesophageal adenocarcinoma
- Anti-reflux surgery to induce remission of disease or prevent recurrence
- Anti-reflux surgery to reduce progression to dysplasia or cancer
Other supporting evidence
This page was last updated: